FI875619A - 6-benzoxazinyl- och 6-benzotiazonyl-2,3,4,5-tetrahydropyridazin-3-oner. - Google Patents

6-benzoxazinyl- och 6-benzotiazonyl-2,3,4,5-tetrahydropyridazin-3-oner. Download PDF

Info

Publication number
FI875619A
FI875619A FI875619A FI875619A FI875619A FI 875619 A FI875619 A FI 875619A FI 875619 A FI875619 A FI 875619A FI 875619 A FI875619 A FI 875619A FI 875619 A FI875619 A FI 875619A
Authority
FI
Finland
Prior art keywords
benzotiazonyl
tetrahydropyridazin
oner
benzoxazinyl
och
Prior art date
Application number
FI875619A
Other languages
English (en)
Other versions
FI86425B (fi
FI875619A0 (fi
FI86425C (fi
Inventor
Donald W Combs
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/944,316 external-priority patent/US4721784A/en
Priority claimed from US07/064,638 external-priority patent/US4766118A/en
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of FI875619A0 publication Critical patent/FI875619A0/fi
Publication of FI875619A publication Critical patent/FI875619A/fi
Publication of FI86425B publication Critical patent/FI86425B/fi
Application granted granted Critical
Publication of FI86425C publication Critical patent/FI86425C/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/141,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/161,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
FI875619A 1986-12-22 1987-12-21 Foerfarande foer framstaellning av terapeutiskt aktiva 6-benzoxazinyl- och 6-benzotiazinyl-2,3,4,5- tetrahydropyridazin-3-oner. FI86425C (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US94431686 1986-12-22
US06/944,316 US4721784A (en) 1986-12-22 1986-12-22 6-benzoxazinyl-2,3,4,5-tetrahydropyridazin-3-ones
US6463887 1987-06-22
US07/064,638 US4766118A (en) 1986-12-22 1987-06-22 6-benzoxazinyl- and 6-benzothiazinyl-2,3,4,5-tetrahydropyridazin-3-ones and pharmaceutical use
US12514287A 1987-12-02 1987-12-02
US12514287 1987-12-02

Publications (4)

Publication Number Publication Date
FI875619A0 FI875619A0 (fi) 1987-12-21
FI875619A true FI875619A (fi) 1988-06-23
FI86425B FI86425B (fi) 1992-05-15
FI86425C FI86425C (fi) 1992-08-25

Family

ID=27370654

Family Applications (1)

Application Number Title Priority Date Filing Date
FI875619A FI86425C (fi) 1986-12-22 1987-12-21 Foerfarande foer framstaellning av terapeutiskt aktiva 6-benzoxazinyl- och 6-benzotiazinyl-2,3,4,5- tetrahydropyridazin-3-oner.

Country Status (12)

Country Link
EP (1) EP0272914A3 (fi)
KR (1) KR880007527A (fi)
AU (2) AU607731B2 (fi)
DK (1) DK673087A (fi)
FI (1) FI86425C (fi)
HU (1) HU207314B (fi)
IL (1) IL84832A (fi)
MY (2) MY102280A (fi)
NO (1) NO173653C (fi)
NZ (1) NZ222843A (fi)
PH (1) PH24498A (fi)
PT (1) PT86453B (fi)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3934436A1 (de) * 1989-06-01 1991-04-18 Thomae Gmbh Dr K 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
TW224941B (fi) * 1989-11-08 1994-06-11 Yamanouchi Pharma Co Ltd
US5221742A (en) * 1990-12-21 1993-06-22 Ortho Pharmaceutical Corporation Process for the preparation of 6-(3,4-dihydro-3-oxo-1,4(2h)-benzoxazin-7-yl)-2,3,4,5-tetrahydropyridazin-3-ones
AU1493092A (en) * 1991-04-18 1992-10-22 Ortho Pharmaceutical Corporation (+) and (-) enantiomers of 5-aliphatic-6-(benzoxazinyl- or benzothiazinyl)-2,3,4,5-tetrahydropyridazin-3-ones
CN1202159A (zh) * 1995-09-22 1998-12-16 住友化学工业株式会社 吡嗪-2-酮衍生物,它们的应用及用于制备它们的中间体
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005099688A2 (en) 2004-04-07 2005-10-27 Takeda Pharmaceutical Company Limited Cyclic compounds
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN108676076A (zh) 2011-03-01 2018-10-19 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2014131024A2 (en) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法
MX2016001714A (es) 2013-08-09 2016-10-03 Ardelyx Inc Compuestos y metodos para inhibir el transporte de fosfato.
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2035749A1 (fi) * 1969-02-06 1970-12-24 Bellon Labor Sa Roger
FR2588868B1 (fr) * 1985-10-21 1988-11-10 Negma Laboratoires Acyl-7 benzoxazinones et leurs derives, procede pour les obtenir et compositions pharmaceutiques les contenant
TW224941B (fi) * 1989-11-08 1994-06-11 Yamanouchi Pharma Co Ltd

Also Published As

Publication number Publication date
EP0272914A3 (en) 1990-04-04
AU8293287A (en) 1988-06-23
AU607731B2 (en) 1991-03-14
HUT48624A (en) 1989-06-28
PT86453B (pt) 1990-11-20
NZ222843A (en) 1989-10-27
HU207314B (en) 1993-03-29
DK673087D0 (da) 1987-12-21
IL84832A0 (en) 1988-06-30
FI86425B (fi) 1992-05-15
NO173653B (no) 1993-10-04
PT86453A (en) 1988-01-01
FI875619A0 (fi) 1987-12-21
AU633666B2 (en) 1993-02-04
MY102280A (en) 1992-05-15
DK673087A (da) 1988-06-23
FI86425C (fi) 1992-08-25
EP0272914A2 (en) 1988-06-29
KR880007527A (ko) 1988-08-27
PH24498A (en) 1990-07-18
NO875358D0 (no) 1987-12-21
IL84832A (en) 1993-01-14
NO173653C (no) 1994-01-12
AU6808690A (en) 1991-04-26
NO875358L (no) 1988-06-23
MY106781A (en) 1995-07-31

Similar Documents

Publication Publication Date Title
DE3783669D1 (de) Alpha-aryl-alpha-phenethyl-1h-1,2,4-triazol-1-propan-nitrile.
DE3764686D1 (de) N,n'-dihalo-2-imidazolidinone.
LV5742B4 (lv) 3,5-divalizvietoti pirokatehina atvasinajumi
FI873584A (fi) Mjuk, sockerfri, poroes soetsaks- resp. bakverkssammansaettning.
FI872594A (fi) Cementprodukter, vilka innehaoller ytbehandlade oorganiska partiklar.
FI875619A (fi) 6-benzoxazinyl- och 6-benzotiazonyl-2,3,4,5-tetrahydropyridazin-3-oner.
DE3763411D1 (de) 1,2,3,6-tetrahydro-5-nitro-pyrimidin-derivate.
FI874428A0 (fi) Foerfarande foer framstaellning av vinylklorid medelst termisk spjaelkning av 1,2-dikloretan.
FI872267A (fi) Stabila, vattenhaltiga suspensionskoncentratkompositioner.
FI874864A (fi) Oformade, eldfasta massor.
DE3765646D1 (de) 2,5,6,7-tetranor-4,8-inter-m-phenylen-pgi2-derivate.
FI881829A (fi) 1,3-dioxaner.
FI880552A (fi) Substituerade 2,6-substituerade pyridinfoereningar.
FI872598A (fi) N-1h-tetrazol-5-yl-2-tiofen-, n-1h -tetrazol-5-yl-2-pyrrol- och n-1h-tetrazol-5-yl-2-furankarboxamider.
ES2015605B3 (es) 3,4-dihidro-2h-piranos.
FI873116A (fi) Foerfarande foer framstaellning av 1,3,5-tritianderivat.
FI880081A0 (fi) 2,1-bensotiazepin-2,2-dioxid-5 -karboxylsyraderivat.
FI875128A (fi) Kabelmuff, isynnerhet en intagningskabelmuff foer partraods intagningskabel.
FI874479A0 (fi) Golvskoetselanordning, speciellt munstycke foer dammsugare.
FI871432A (fi) Foerkopplingsdrossel, speciellt foer gasurladdningslampor.
FI870924A0 (fi) Aromatiska -alkylimino-tetrahydro-6h -1,3-tiazin-6-onderivater.
DE3761091D1 (de) 2,6-dimethyl-p-benzochinontetraalkylketale.
ATE54146T1 (de) 1,2,3,6-tetrahydro-5-nitro-pyrimidin-derivate.
ATE50254T1 (de) 3,4-dihydro-4-oxo-2h-1-benzopyranyloxy-alkansaeu e-derivate.
DE3770251D1 (de) 1,1,2-triaryl-1-buten-derivate.

Legal Events

Date Code Title Description
MM Patent lapsed
MM Patent lapsed

Owner name: ORTHO PHARMACEUTICAL CORPORATION